BMC Urology, 2021 Objective To assess the use and safety of free combination therapy (dutasteride and tamsulosin), dutasteride monotherapy, or tamsulosin monotherapy in patients with benign prostatic hyperplasia (BPH).
Zrinka Lulic +9 more
doaj +1 more source
Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors:population based cohort study [PDF]
, 2019 OBJECTIVE: To investigate the incidence of new onset type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors (dutasteride or finasteride) for long term treatment of benign prostatic hyperplasia.
Andrew, Ruth +5 more
core +4 more sources
Is the Safety of Finasteride Correlated With Its Route of Administration: Topical Versus Oral? A Pharmacovigilance Study With Data From the United States Food and Drug Administration Adverse Event Reporting System. [PDF]
Int J DermatolABSTRACT Background The United States Food and Drug Administration (FDA) approved oral finasteride for androgenetic alopecia. In 2022, approximately 2.6 million U.S. men used it for hair loss and prostate conditions. Post‐finasteride syndrome (PFS), proposed in 2012, involves persistent sexual and neuropsychiatric adverse events (AEs) after cessation ...
Gupta AK +3 more
europepmc +2 more sources
Patient's adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: Is combination therapy better than monotherapy [PDF]
, 2015 BACKGROUND: Recent studies showed that the non-adherence to the pharmacological therapy of patients affected by BPH-associated LUTS increased the risk of clinical progression of BPH.
Antonelli, Alessandro +10 more
core +1 more source
Preparation and Characterization of Dutasteride Nanoparticles as Oral Fast-Dissolving Film
مجلة كلية الطبBackground: Dutasteride, is a drug whose mechanism of action is inhibition of the enzyme 5-alpha reductase. It has been approved for use in the treatment of benign prostatic hyperplasia.
Rusul W. Kadhum +1 more
doaj +1 more source
pharma-kritik, 2004 Ein zweiter 5alpha-Reduktasehemmer zur Behandlung der benignen Prostatahyperplasie. Dutasterid hat eine ungewöhnlich lange Halbwertszeit und erscheint nach bisherigem Wissen als ähnlich wirksam wie Finasterid. Die Symptome der Prostathyperplasie werden von diesen Substanzen eher weniger gut gelindert als von Alphablockern.
openaire +1 more source
Frontiers in Oncology, 2019 Background: To evaluate the efficacy of early dutasteride administration in patients with a detectable prostate-specific antigen (PSA) levels after robot-assisted radical prostatectomy (RARP).Methods: We retrospectively analyzed RARP patients whose ...
Chin-Heng Lu +7 more
doaj +1 more source
Magnetic resonance imaging in active surveillance-a modern approach [PDF]
, 2018 In recent years, active surveillance has been increasingly adopted as a conservative management approach to low and sometimes intermediate risk prostate cancer, to avoid or delay treatment until there is evidence of higher risk disease.
Giganti, F, Moore, CM
core +1 more source
Dermatology ReportsNowadays androgenetic alopecia (AGA) has become a common concern of affected subjects of both sexes. Finasteride is approved by the Food and Drug Administration for the treatment of male AGA.
Almuntaserbellah Almudaimeegh +4 more
doaj +1 more source
Trasplante de Pelo en la Alopecia Fibrosante Frontal: ¿Parte de la Solución? [PDF]
, 2016 info:eu-repo/semantics ...
Camps-Fresneda, A, Mendes-Bastos, P
core +1 more source